Literature DB >> 28516359

Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.

Nadia Bou-Chacra1, Katherine Jasmine Curo Melo1, Ivan Andrés Cordova Morales1, Erika S Stippler2, Filippos Kesisoglou3, Mehran Yazdanian4, Raimar Löbenberg5.   

Abstract

The introduction of the biopharmaceutics drug classification system (Biopharmaceutics Classification System (BCS)), in 1995, provided a simple way to describe the biopharmaceutics behavior of a drug. Solubility and permeability are among the major parameters, which determine the fraction dose absorbed of a drug substance and consequently its chances to be bioavailable. The purpose of this review is to summarize the evolution of the media used for determining solubility and dissolution and how this can be used in modern drug development. Over the years, physiologically adapted media and buffers were introduced with the intention to better predict the in vivo solubility and dissolution of drug substances. Water, buffer solutions, compendial media, micellar solubilization media, and biorelevant media are reviewed. At this time point, there is no universal medium available which can be used to predict every drug substance's solubility or a drug product's in vivo dissolution behavior. However, there have been many improvements and additions made to media to optimize their in vivo predictability; for example, the current phosphate concentrations in buffers seem to be too high to correlate with the carbonate buffer concentrations in vivo. Biorelevant media were updated to correlate them better with the composition of human intestinal fluids. The BCS was introduced into regulatory sciences as a scientific risk management tool to waive bioequivalence studies under certain conditions. Today's different guidance documents define the dose-solubility ratio differently. As shown for amoxicillin, this can cause more confusion than certainty for globally operating companies. Harmonization of BCS guidelines is highly desirable.

Entities:  

Keywords:  BCS; IVIVC; dissolution; solubility

Mesh:

Substances:

Year:  2017        PMID: 28516359     DOI: 10.1208/s12248-017-0085-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  99 in total

1.  Novel milk-based oral formulations: proof of concept.

Authors:  Georgia Charkoftaki; John Kytariolos; Panos Macheras
Journal:  Int J Pharm       Date:  2010-02-01       Impact factor: 5.875

2.  Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.

Authors:  Maria Vertzoni; Jennifer Dressman; James Butler; John Hempenstall; Christos Reppas
Journal:  Eur J Pharm Biopharm       Date:  2005-08       Impact factor: 5.571

Review 3.  Current perspectives in dissolution testing of conventional and novel dosage forms.

Authors:  Shirzad Azarmi; Wilson Roa; Raimar Löbenberg
Journal:  Int J Pharm       Date:  2006-10-06       Impact factor: 5.875

4.  The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs.

Authors:  Sung-Hyun Park; Hoo-Kyun Choi
Journal:  Int J Pharm       Date:  2006-05-09       Impact factor: 5.875

5.  Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.

Authors:  Arthur Okumu; Marie DiMaso; Raimar Löbenberg
Journal:  Pharm Res       Date:  2008-06-17       Impact factor: 4.200

6.  Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant.

Authors:  J Jinno; D m Oh; J R Crison; G L Amidon
Journal:  J Pharm Sci       Date:  2000-02       Impact factor: 3.534

7.  The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.

Authors:  Thao Thi Do; Michiel Van Speybroeck; Raf Mols; Pieter Annaert; Johan Martens; Jan Van Humbeeck; Jan Vermant; Patrick Augustijns; Guy Van den Mooter
Journal:  Int J Pharm       Date:  2011-05-07       Impact factor: 5.875

8.  Coamorphous repaglinide-saccharin with enhanced dissolution.

Authors:  Yuan Gao; Jiao Liao; Xuan Qi; Jianjun Zhang
Journal:  Int J Pharm       Date:  2013-04-21       Impact factor: 5.875

9.  Telmisartan complex augments solubility, dissolution and drug delivery in prostate cancer cells.

Authors:  Manveet Kaur; Richa Kaur Bhatia; Raghuvir R S Pissurlenkar; Evans C Coutinho; Upendra Kumar Jain; Om Prakash Katare; Ramesh Chandra; Jitender Madan
Journal:  Carbohydr Polym       Date:  2013-09-30       Impact factor: 9.381

10.  Evaluation of solubility and partition properties of ampicillin-based ionic liquids.

Authors:  Catarina Florindo; João M M Araújo; Filipa Alves; Carla Matos; Ricardo Ferraz; Cristina Prudêncio; João Paulo Noronha; Željko Petrovski; Luís Branco; Luís Paulo N Rebelo; Isabel M Marrucho
Journal:  Int J Pharm       Date:  2013-08-23       Impact factor: 5.875

View more
  10 in total

1.  Biowaiver Applications in Support of a Polymorph During Late-Stage Clinical Development of Verubecestat-Current Challenges and Future Opportunities for Global Regulatory Alignment.

Authors:  Andreas Abend; Leah Xiong; Xiaohua Zhang; Celeste Frankenfeld; Filippos Kesisoglou; Kevin Reuter; Pramod Kotwal
Journal:  AAPS J       Date:  2019-12-20       Impact factor: 4.009

2.  Exploratory Study on Lercanidipine Hydrochloride Polymorphism: pH-Dependent Solubility Behavior and Simulation of its Impact on Pharmacokinetics.

Authors:  Ilia Alekseevich Repin; Raimar Loebenberg; John DiBella; António C L Conceição; Manuel E Minas da Piedade; Humberto G Ferraz; Michele G Issa; Nadia A Bou-Chacra; Catharine F M Ermida; Gabriel L B de Araujo
Journal:  AAPS PharmSciTech       Date:  2021-01-21       Impact factor: 3.246

3.  Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media.

Authors:  Dong Ye; Álvaro López Mármol; Verena Lenz; Patricia Muschong; Anita Wilhelm-Alkubaisi; Manuel Weinheimer; Mirko Koziolek; Kerstin A Sauer; Loic Laplanche; Mario Mezler
Journal:  Pharmaceutics       Date:  2022-03-24       Impact factor: 6.525

4.  Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.

Authors:  Lucija Vuletić; M Zahirul I Khan; Drago Špoljarić; Maja Radić; Biserka Cetina-Čižmek; Jelena Filipović-Grčić
Journal:  Pharm Res       Date:  2018-06-22       Impact factor: 4.200

5.  Topography of Simulated Intestinal Equilibrium Solubility.

Authors:  Claire Dunn; Jeremy Perrier; Ibrahim Khadra; Clive G Wilson; Gavin W Halbert
Journal:  Mol Pharm       Date:  2019-04-16       Impact factor: 4.939

6.  Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems.

Authors:  Qamar Abuhassan; Ibrahim Khadra; Kate Pyper; Patrick Augustijns; Joachim Brouwers; Gavin W Halbert
Journal:  Eur J Pharm Biopharm       Date:  2021-12-16       Impact factor: 5.571

7.  Small scale in vitro method to determine a bioequivalent equilibrium solubility range for fasted human intestinal fluid.

Authors:  Qamar Abuhassan; Ibrahim Khadra; Kate Pyper; Gavin W Halbert
Journal:  Eur J Pharm Biopharm       Date:  2021-08-20       Impact factor: 5.571

8.  On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.

Authors:  Patrick J O'Dwyer; Karl J Box; Georgios Imanidis; Maria Vertzoni; Christos Reppas
Journal:  Eur J Pharm Sci       Date:  2021-10-07       Impact factor: 4.384

Review 9.  Power of the Dissolution Test in Distinguishing a Change in Dosage Form Critical Quality Attributes.

Authors:  Vivian A Gray
Journal:  AAPS PharmSciTech       Date:  2018-10-22       Impact factor: 3.246

10.  Evaluating pediatric and adult simulated fluids solubility: Abraham solvation parameters and multivariate analysis.

Authors:  Mariana Guimarães; Martin Kuentz; Maria Vertzoni; Nikoletta Fotaki
Journal:  Pharm Res       Date:  2021-10-25       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.